Patient specific induced pluripotent stem cell derived macrophages for cell based therapy

Abstract

Described herein are compositions, pharmaceutical compositions, methods, methods of administration, and kits related to cellular therapy for cancer, in particular glioblastoma. In certain aspects, cells can be isolated from a patient, reprogrammed using methods as described herein to a pluripotent state, and then differentiated into cells with a macrophage or macrophage-like phenotype. Differentiated (or terminally-differentiated) cells can then be readministered to a patient in need thereof, for example, a patient with a cancer (for example a glioblastoma). In other aspects, reprogrammed cells can be from a patient's blood, plasma, tissue (for example, a periosteum sample), or other cell source. In other aspects, terminally-differentiated cells can also be genetically modified for self-destruction or for the production of exogenous (or enhanced production of endogenous) cytokines, growth factors, or other peptide-based therapeutics.

Dependencies are inferred from the claim text.